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Abstract
Background: We have recently demonstrated in man that a functional allelic polymorphism in the
Haptoglobin (Hp) gene plays a major role in determining survival and congestive heart failure after
myocardial infarction (MI). We sought to recapitulate the effect of Hp type on outcomes and
cardiac remodeling after MI in transgenic mice.
Methods: The Hp 2 allele exists only in man. Wild type C57Bl/6 mice carry the Hp 1 allele with
high homology to the human Hp 1 allele. We genetically engineered a murine Hp 2 allele and
targeted its insertion by homologous recombination to the murine Hp locus to create Hp 2 mice.
Diabetes Mellitus (DM) was induced with streptozotocin. MI was produced by occlusion of the left
anterior descending artery in DM C57Bl/6 mice carrying the Hp 1 or Hp 2 allele. MI size was
determined with TTC staining. Left ventricular (LV) function and dimensions were assessed by 2-
dimensional echocardiography.
Results: In the absence of DM, Hp 1-1 and Hp 2-2 mice had similar LV dimensions and LV function.
MI size was similar in DM Hp 1-1 and 2-2 mice 24 hours after MI (50.2 ± 2.1%and 46.9 ± 5.5%,
respectively, p = 0.6). However, DM Hp 1-1 mice had a significantly lower mortality rate than DM
Hp 2-2 mice 30 days after MI (HR 0.41, 95% CI (0.19–0.95), p = 0.037 by log rank). LV chamber
dimensions were significantly increased in DM Hp 2-2 mice compared to DM Hp 1-1 mice 30 days
after MI (0.196 ± 0.01 cm2 vs. 0.163 ± 0.01 cm2, respectively; p = 0.029).
Conclusion: In DM mice the Hp 2-2 genotype is associated with increased mortality and more
severe cardiac remodeling 30 days after MI.
Background
The increasing burden of cardiovascular diseases (CVD)
has been unquestionably linked with the growing epi-
demic of diabetes mellitus (DM). CVD is the leading cause
of death in individuals with DM [1]. Conventional risk
factors, such as smoking, hypertension, and hyperlipi-
demia provide a substantial, yet, limited explanation for
the increased risk of CVD in DM [2]. Recent studies have
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further underscored that hyperglycemia is a necessary but
not sufficient condition for the development and progres-
sion of diabetic CVD [3]. Several polymorphic genetic loci
have recently been identified that may serve as important
determinants of the susceptibility to and rate of progres-
sion of cardiovascular complications in DM [4-9]. One
such polymorphic locus is that encoding the gene for
Haptoglobin (Hp) [10,11].
Hp is an acute phase serum protein whose main known
function is binding and scavenging of free hemoglobin
through the liver or circulating monocytes [12-14]. In
man there exist a functional polymorphism in the Hp
gene with two common alleles denoted 1 and 2 that result
in three possible genotypes. The Hp protein produced by
the Hp 1 and Hp 2 alleles differs markedly both in its
structure and function. In a post hoc analysis of clinical
trials comprising several thousand patients we have found
that the Hp 2-2 genotype is an independent risk factor for
cardiovascular complications in DM [11,15-17].
In particular we have demonstrated that the Hp genotype
is a determinant of congestive heart failure (CHF) and
death after MI in man. Individuals with the Hp 2-2 geno-
type were found to have a 7 fold greater mortality and 4
fold greater incidence of CHF 30 days after MI as com-
pared to Hp 1-1 DM individuals after MI [16].
In this study we sought to determine if this association
between the Hp genotype and DM on outcomes and car-
diac remodeling after MI could be recapitulated in trans-
genic mice.
Methods
Animals
All protocols used in these studies were approved by the
Technion Faculty of Medicine Animal Care and Use Com-
mittee. The Hp 2 allele exists only in man. Wild type
C57Bl/6 mice carry only the Hp 1 allele with a high
homology to the human Hp 1 allele [18].
We genetically engineered a murine Hp 2 allele and tar-
geted its insertion by homologous recombination to the
murine Hp locus to create Hp 2-2 mice as previously
described [19].
Diabetes
DM was induced at 2–3 month of age by IP injection of 50
mg/kg of streptozotocin (STZ) on 5 consecutive days.
Blood glucose levels were monitored once a week with
DM being defined as a consistent blood glucose level
higher than 200 mg/dl.
MI
Myocardial infarction was produced using a modification
of a previously described ischemia-reperfusion model
[20]. Briefly, mice were anesthetized with a mixture of ket-
amine (150 mg/kg) and xylazine (9 mg/kg) and the tra-
chea intubated and connected to a small rodent respirator
(MiniVent 845, Harvard Apparatus). The chest was
opened by a left lateral thoracotomy and after removal of
the pericardium a ligation of the left anterior descending
coronary artery (LAD) was done using 7/0 prolene non-
absorbable suture thereby permanently occluding blood
flow to the myocardium distal to the ligature. The mouse
was then weaned off from ventilation and allowed to
awaken. The procedure was done under vision with a ster-
eoscopic zoom microscope (Nikon SMZ800). Mice were
studied for up to 30 days after the MI and then sacrificed.
Infarct size
Hearts were harvested 24 h after MI. After the right ventri-
cle was removed the left ventricle was cooled for 5–10
minutes and then cut into five 3 mm thick slices along its
short axis. All slices were weighed and then incubated at
37° in 1% 2,3,5 – triphenyltetrazoliumchloride (TTC) in
phosphate saline buffer (pH 7.0) for 20 minutes. After
incubation in TTC the slices were photographed and the
images were used for planimetric analysis to determine
relative infarct size of the total LV area.
Echocardiography
Trans-thoracic echocardiography was performed with a
commercially available echocardiography system
equipped with a 15-MHz phased-array linear transducer
(General Electric) by a single experienced operator who
was blinded to the Hp genotype and to the time point at
which the data was recorded. Animals were sedated with
a low dose mixture of ketamine (50 mg/kg) and xylazine
(3 mg/kg). Animals underwent three echocardiography
examinations. A baseline examination was preformed 24–
48 hours prior to the operation, a second examination 4
days after the operation and a third examination 30 days
after the operation.
We measured maximal left ventricular end-diastolic diam-
eter (LVEDd) and area (LVEDa) and minimal LV end-
systolic diameter (LVESd) and area (LVESa) in 2-D mode
imaging. Fractional shortening (FS), as a measure of systo-
lic function was calculated as: FS (%) = [(LVEDd-LVESd)/
LVEDd] × 100. For the analysis we averaged measure-
ments of 3 consecutive cardiac cycles.
Statistical analysis
Groups were compared using the Student t test. A p value
of < 0.05 was considered statistically significant.Cardiovascular Diabetology 2009, 8:29 http://www.cardiab.com/content/8/1/29
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Results
Baseline characteristics of mice used in this study
After 6 weeks of DM, Hp 1-1 or Hp 2-2 mice were sub-
jected to either a MI or a sham procedure. Table 1 presents
baseline characteristics of the four groups (Hp 1-1 MI, Hp
1-1 sham, Hp 2-2 MI, Hp 2-2 sham) taken on the same
day and prior to the surgical procedure (coronary ligation
or sham procedure). Baseline characteristics were similar
between MI and sham groups of the same genotype.
Myocardial infarction size is similar in Hp 1-1 and Hp 2-2 
mice
Figure 1 demonstrates infarct size in Hp 1-1 or Hp 2-2 DM
mice 24 hours after complete LAD occlusion. MI size was
calculated as infarct area relative to total LV area and
adjusted to heart section weight. We found no difference
in MI size between Hp 1-1 and Hp 2-2 DM mice (50.2 ±
2.1% and 47.0 ± 5.6%, respectively; p = 0.6).
Survival is decreased after MI in Hp 2-2 DM mice
In spite of the similar MI size found in Hp 1-1 and Hp 2-
2 DM mice, Hp 1-1 mice had a significantly higher sur-
vival rate during the 30 days after MI compared to Hp 2-2
mice (69.57% vs. 36.67%, respectively; HR 0.41, 95% CI
(0.19–0.95), p = 0.037 by log rank) (Figure 2). There was
no difference in survival between Hp 1-1 and Hp 2-2
sham operated mice (83.33% vs. 72.22%, respectively; p
= 0.33).
Left ventricular area is markedly increased in Hp 2-2 DM 
mice after MI
Mice in all four groups underwent three echocardiography
examinations as detailed in Methods. At day 0, before any
surgical intervention, LVEDa was similar between all four
groups. In both Hp genotypes LVEDa was significantly
increased at day 4 and day 30 after MI as compared to day
0 (p < 0.0001 at day 30 for Hp 1-1 and for Hp 2-2) (Figure
3A). However, LVEDa was significantly larger in Hp 2-2
mice as compared to Hp 1-1 mice 30 days after MI (0.196
cm2 vs. 0.163 cm2, respectively, p = 0.029) (Figure 3A).
The net change in LVEDa 30 days after MI was 0.11 cm2
and 0.07 cm2 for Hp 2-2 and Hp 1-1, respectively (p =
0.027).
In a sub-analysis we found that only in mice with the Hp
2-2 genotype was there a relationship between the
increase in LVEDa four days after MI and early mortality
(death within two weeks of the MI procedure). The rela-
tive change in LVEDa four days after MI was 121.35% in
Hp 2-2 mice which died within two weeks of the MI (8.7
days on average) vs. 64.32% in Hp 2-2 mice which lived
more than two weeks after the MI (27 days on average), p
= 0.044. This phenomenon of an increased LVEDa in mice
who died prematurely was not found in Hp 1-1 mice (Fig-
ure 4).
Left ventricle function after MI\sham in DM
LV function was expressed by fractional shortening (FS) as
described in Methods. The baseline FS was similar in Hp
1-1 and Hp 2-2 mice before MI. LV function was non-sig-
nificantly better in Hp 1-1 mice as compared to Hp 2-2
mice at day 4 and day 30 after MI (Figure 5A); Moreover,
in the Hp 2-2 group, 52% of the mice had at least a 50%
reduction in FS 30 days after MI compared to 25% of the
mice in the Hp 1-1 group (p = 0.066).
Discussion
In this study we have demonstrated that Hp 2-2 DM mice
have increased mortality and more severe cardiac remod-
eling after MI as compared to Hp 1-1 DM mice. These data
therefore appear to recapitulate the association between
Hp type and MI outcomes which we have previously
found in man [16].
These results cannot be explained by differences in infarct
size between the Hp 1-1 and Hp 2-2 mice. Prior studies
showing an effect of Hp genotype on myocardial injury
were done in an ischemia-reperfusion model using a
reversible closure of the LAD while in the present study we
have used a fixed occlusion of the LAD [20].
It is not clear why Hp 2-2 DM mice had a higher mortality
rate compared to Hp 1-1 DM mice. Hp 2-2 DM mice
which died within 14 days after MI had significantly more
severe cardiac enlargement as compared to those Hp 2-2
mice which completed the study protocol and lived 30
days. Early mortality of more severely remodeled Hp 2-2
DM hearts may have been the reason why we were not
Table 1: Baseline characters of diabetic mice subjected to MI\Sham procedure
Hp 1-1 Hp 2-2
MI Sham P value MI Sham P value
Age (days) 132(14) 130(9) 0.73 137(12) 129(14) 0.051
Diabetes duration (days) 44(4.6) 44(4.4) 0.76 45(5.4) 42(4) 0.058
Body weight (g) 21.65(2.3) 21.8(2.7) 0.82 21.2(3.5) 21.7(3.2) 0.61
Females (%) 34.8 16.7 0.19 33.3 22.2 0.41
Blood glucose (mg/dL) 456(117) 532(51) 0.02 511(111) 500(111) 0.74
Numbers are mean value (S.D.). N = 23 and 18 for Hp 1-1 (MI and sham, respectively) and n = 30 and 18 for Hp 2-2 (MI and sham, respectively).Cardiovascular Diabetology 2009, 8:29 http://www.cardiab.com/content/8/1/29
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MI size is similar in Hp 1-1 and Hp 2-2 mice 24 hours after MI Figure 1
MI size is similar in Hp 1-1 and Hp 2-2 mice 24 hours after MI. Data shown is average ± S.D. n = 6 for Hp 1-1 and n 
= 7 for Hp 2-2. p = 0.6.
30 day survival after MI is increased in Hp 1-1 mice as compared to Hp 2-2 mice Figure 2
30 day survival after MI is increased in Hp 1-1 mice as compared to Hp 2-2 mice. N = 23 for Hp 1-1 and n = 30 for 
Hp 2-2. HR 0.41, 95% CI (0.19–0.95), p = 0.037 by log rank.Cardiovascular Diabetology 2009, 8:29 http://www.cardiab.com/content/8/1/29
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Left ventricle end-diastolic area in DM mice after MI\Sham procedure Figure 3
Left ventricle end-diastolic area in DM mice after MI\Sham procedure. Values are mean ± S.D. N = 22, 20, and 15 in 
Hp 1-1 mice (for day 0, 4, and 30 respectively). N = 29, 26, and 9 in Hp 2-2 mice (for day 0, 4, and 30 respectively). A – LVEDa. 
* p = 0.010 vs. 'DAY 0'; † p < 0.0001 vs. 'DAY 0'; §p = 0.012 vs. Hp 1-1; ‡ p = 0.0013 vs. Hp 1-1. B – Relative change in LVEDa 
compared to 'Day 0'. † p = 0.0001 vs. sham; ‡ p < 0.0001 vs. sham; * p = 0.002 vs. sham.
A
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able to demonstrate a significant decline in LV function in
the Hp 2-2 DM mice.
Hp is expressed in the arterial wall and is involved in arte-
rial remodeling by mediating ECM breakdown by inhibit-
ing the activity of gelatinases and promoting cell
migration [21]. This finding may apply to myocardial tis-
sue as well. Hp has been shown to be increased in myo-
cardial interstitial fluid after myocardial ischemia and
regulates coronary collateralization after repetitive coro-
nary occlusion [22]. It is possible then, that these func-
tions of Hp may be genotype dependent and therefore
affect early phase remodeling after MI.
Conclusion
In this study we have recapitulated in a transgenic mice
model the epidemiological association we have found in
man between Hp genotype, death and cardiac remode-
ling. Therefore, this novel transgenic mouse model may
serve as a platform to study the basic mechanisms that
underlie cardiac remodeling which are Hp genotype
dependent and to search for interventions aimed to mod-
ulate this process and attenuate the rapid progression of
heart failure and decrease the high mortality rate after MI
in Hp 2-2 DM individuals which make up 40% of the DM
community.
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Change in LV end-diastolic area 4 days after MI, segregated  by Hp genotype and survival Figure 4
Change in LV end-diastolic area 4 days after MI, seg-
regated by Hp genotype and survival. Values are mean 
± S.D. N = 14 and 15 for Hp 1-1 mice (under and over 2 
weeks, respectively). N = 11 and 5 for Hp 2-2 mice (under 
and over 2 weeks, respectively). * p = 0.044 vs. Hp 2-2 that 
survived more than 2 weeks.
Left ventricle function in DM mice after MI Figure 5
Left ventricle function in DM mice after MI. Values are 
mean ± S.D. N = 22, 20, and 15 in Hp 1-1 mice (for day 0, 4, 
and 30 respectively). N = 29, 26, and 9 in Hp 2-2 mice (for 
day 0, 4, and 30 respectively). A – Left ventricle function after 
MI. p = 0.42 at day 0, 0.1 at day 4, and 0.34 at day 30. B – Rel-
ative change in FS after MI compared to day 0. * p = 0.039 vs. 
Hp 1-1.
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